XML 43 R31.htm IDEA: XBRL DOCUMENT v3.6.0.2
FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended
Dec. 31, 2016
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities
The following tables present the Company’s financial assets and liabilities measured on a recurring basis using the fair value hierarchy at December 31, 2016 and March 31, 2016 (in thousands):

Fair Value Measurements at
 
December 31, 2016
 
Level 1

Level 2

Level 3

Total
ASSETS:

 

 



Cash and cash equivalents
$
244,833

 
$

 
$

 
$
244,833

U.S. government and municipal obligations
35,384

 
70,856

 


106,240

Commercial paper

 
21,153

 


21,153

Corporate bonds
4,683

 

 


4,683

Derivative financial instruments

 
9

 


9


$
284,900

 
$
92,018

 
$


$
376,918

LIABILITIES:

 

 



Contingent purchase consideration
$

 
$

 
$
(5,410
)

$
(5,410
)
Derivative financial instruments

 
(391
)
 


(391
)

$

 
$
(391
)
 
$
(5,410
)

$
(5,801
)

Fair Value Measurements at
 
March 31, 2016
 
Level 1

Level 2

Level 3

Total
ASSETS:

 

 



Cash and cash equivalents
$
210,711

 
$

 
$


$
210,711

U.S. government and municipal obligations
41,116

 
82,212

 


123,328

Commercial paper

 
16,172

 


16,172

Corporate bonds
1,864

 

 


1,864

Derivative financial instruments

 
191

 

 
191

Contingently returnable consideration

 

 
16,131

 
16,131


$
253,691


$
98,575


$
16,131


$
368,397

LIABILITIES:

 

 



Contingent purchase consideration
$

 
$

 
$
(7,293
)

$
(7,293
)
Derivative financial instruments

 
(158
)
 


(158
)

$


$
(158
)

$
(7,293
)

$
(7,451
)
Schedule of Reconciliation of Changes in Fair Value of Level III Financial Assets
The following table sets forth a reconciliation of changes in the fair value of the Company’s Level 3 financial assets and liabilities for the nine months ended December 31, 2016 (in thousands):

Contingent
Purchase
Consideration
 
Contingently Returnable Consideration
Balance at March 31, 2016
$
(7,293
)
 
$
16,131

Additions to Level 3
(660
)
 

Increase in fair value and accretion expense (included within research and development expense)
(114
)
 

Decrease in fair value

 
(610
)
Gross presentation of contingently returnable consideration to contingent purchase consideration
(3,910
)
 
3,910

Payment received

 
(19,431
)
Payments made
6,567

 

Balance at December 31, 2016
$
(5,410
)
 
$